ZBIO
Zenas BioPharma, Inc.
There isn't enough reported data to score ZBIO yet.
ZBIO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
ZBIO's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
ZBIO PE Valuation
ZBIO has no meaningful PE right now: it lost money over the past year.
ZBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Decline | |
| -- | |
| Limited | |
| High |
Analysts expect ZBIO's revenue to decline, with its earnings and profitability holding steady.
ZBIO Earnings Per Share
ZBIO lost $10.05 per share over the past year, a bigger loss than the year before.
ZBIO Quarterly Revenue
ZBIO's revenue is growing: $10M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1034% | N/A |
| Q2 2026 | -10766% | N/A |
| Q1 2025 | -373% | N/A |
| Q3 2023 | 71% | N/A |
ZBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$58M | -$16.9M |
| Q2 2026 | -$57.2M | -$15.5M |
| Q1 2026 | -$75.2M | -$38.1M |
| Q4 2025 | -$52.4M | -$13.8M |
| Q2 2025 | -$41.7M | -$10.7M |
| Q1 2025 | -$37.1M | -$17.9M |
| Q4 2024 | -$38.6M | -$23.2M |
| Q2 2024 | -$31M | -$10.1M |
ZBIO has burned cash in almost every quarter: −$243M over the past year, against −$159M the year before.
ZBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.8% | +3M shares |
| 1 year | +58% | +24.3M shares |
| 3 years | +73% | +27.8M shares |
ZBIO has 66M diluted shares, up 58% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
ZBIO Net Leverage
ZBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ZBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.9 | Neutral |
| Stochastic | 39.5 | Neutral |
ZBIO's weekly RSI is 51 (neutral) and its Stochastic is 39 (neutral).
ZBIO PE vs Healthcare Sector
ZBIO has no meaningful PE right now: it lost money over the past year.
ZBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 1.2% above |
| 20 week MA | $29.3 | 5.8% below |
| 50 week MA | $26.1 | 5.9% above |
| 100 week MA | $20.4 | 36% above |
ZBIO's trend is mixed: it's above three of its four weekly moving averages, and 36% above its 100-week average.
ZBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $19.0 | $9.84 | -48% |
| 2025 | $9.84 | $42.5 | +332% |
| 2026 YTD | $42.5 | $27.6 | -35% |
ZBIO's yearly returns have swung widely, from +332% in 2025 to −48% in 2024. It's down 35% so far in 2026.